利格列汀对2型糖尿病合并帕金森病患者运动功能影响的临床研究

Clinical research of the effects of linagliptin on the motor function of the patients with type 2 diabetes combined with Parkinson′s disease

目的观察利格列汀对2型糖尿病合并帕金森病患者运动功能的改善情况。方法选取2018年2月至5月湖北省武汉市东湖医院内分泌科门诊及住院2型糖尿病合并帕金森病患者60例,随机分为观察组30例(利格列汀+原治疗方案)和对照组30例(安慰剂+原治疗方案)。分别于治疗前、治疗12周、24周及停用利格列汀12周(治疗36周)检测比较2组患者相关功能指标的变化,并同时采用UPDRS-PART3和Webster量表评估患者运动功能情况。结果2组患者经过治疗12周后UPDRS-PART3和Webster量表评分以及体质量指数(body mass index,BMI)、空腹血糖(fasting blood glucose,FBG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(homeostasis model assessment of insulin resistance,HOMA-IR)、白细胞介素-6(interleukin-6,IL-6)水平均较治疗前比较无差异(P>0.05);24周后观察组UPDRS-PART3和Webster量表评分及HOMA-IR、IL-6水平较治疗前及对照组均明显降低(P<0.05);停用利格列汀12周(治疗第36周)时,观察组UPDRS-PART3和Webster量表评分及HOMA-IR、IL-6水平仍显著低于治疗前及对照组(P<0.05)。结论利格列汀能显著改善2型糖尿病合并帕金森病患者的运动功能。

Objective To observe whether linagliptin could improve the motor function of the patients with type 2 diabetes combined with Parkinson′s disease.Methods Sixty outpatients and inpatients with type 2 diabetes and Parkinson′s disease admitted into the hospital from February to May of 2018 were enrolled for study,and were randomly divided into the observation group and the control group,each consisting of 30 patients.The former received linagliptin plus the original treatment profile,while the latter was given placebo plus the original treatment profile.Detections and analyses were made in related parameters and the motor function in the patients of the 2 groups,before treatment,12 and 24 weeks after treatment as well as after withdrawal of linagliptin.At the same time,the motor function of the patients in the 2 groups were also evaluated by using UPDRS-PART3 and Webster scale.Results Twelve weeks after treatment,no statistical differences could be seen in the UPDRS-PART3 and Webster scores,the body mass index(BMI),the levels of fasting blood glucose(FBG),HbA1 c,homeostasis model assessment of insulin resistance(HOMA-IR)and interleukin-6(IL-6),as compared with those before treatment(P>0.05).Twenty-four weeks after treatment,UPDRS-PART3 and Webster scores,as well as the levels of HOMA-IR and IL-6 were significantly decreased in the observation group compared with those before treatment and those of the control group(P<0.05).At week 12 after withdrawal of linagliptin,UPDRS-PART3 and Webster scores as well as the levels of HOMA-IR and IL-6 were still significantly lower than those before treatment and those of the control group(P<0.05).Conclusion Linagliptin could significantly improve the motor function of the patients with type 2 diabetes complicated with Parkinson′s disease.